REG-Elan Corporation PLC Subset Data from Two Randomized Phase 3 Trials Show TYSABRIÂ® Significantly Improves Health-Related Quality of Life for Crohnâs Disease Patients with Prior Exposure or Inadequate Response to Anti-TNFÎ±